![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/18/2900343/0/en/CG-Oncology-Initiates-Expanded-Access-Program-for-Cretostimogene-Grenadenorepvec.html
https://www.globenewswire.com/news-release/2024/06/06/2894893/0/en/CG-Oncology-Announces-Nature-Medicine-Publication-of-Final-Results-from-CORE-001-Study-of-Cretostimogene-Grenadenorepvec-in-Combination-with-Pembrolizumab-in-BCG-Unresponsive-NMIBC.html
https://www.globenewswire.com/news-release/2024/05/24/2887943/0/en/CG-Oncology-to-Present-Positive-Final-Results-from-Phase-2-CORE-001-Study-of-Cretostimogene-Grenadenorepvec-in-Combination-with-Pembrolizumab-in-BCG-Unresponsive-High-Risk-NMIBC-at.html
https://www.globenewswire.com/news-release/2024/05/09/2878703/0/en/CG-Oncology-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Updates.html
https://www.fiercebiotech.com/biotech/cg-sets-new-bar-bladder-cancer-validating-rare-biotech-ipo-success-story
https://www.globenewswire.com/news-release/2024/05/03/2875231/0/en/Cretostimogene-Monotherapy-Demonstrated-75-2-Complete-Response-Rate-in-High-Risk-BCG-Unresponsive-Non-Muscle-Invasive-Bladder-Cancer.html
https://www.globenewswire.com/news-release/2024/04/26/2870438/0/en/CG-Oncology-to-Host-Virtual-Investor-Event-on-Friday-May-3-2024.html
https://www.globenewswire.com/news-release/2024/04/24/2868754/0/en/CG-Oncology-to-Unveil-Encouraging-Results-on-Cretostimogene-in-Combination-with-Pembrolizumab-at-ASCO-2024.html
https://www.globenewswire.com/news-release/2024/03/28/2853920/0/en/CG-Oncology-to-Present-Results-on-Cretostimogene-at-the-AUA-2024-Annual-Meeting.html
https://www.globenewswire.com//news-release/2024/02/27/2835948/0/en/CG-Oncology-Announces-First-Patient-Dosed-in-PIVOT-006-Phase-3-Clinical-Trial-of-Cretostimogene-in-Intermediate-risk-Non-Muscle-Invasive-Bladder-Cancer.html